InNexus Announces Scientific Publication and Disclosure of a Monoclonal Antibody-Based, Alternative to Small-Molecule Drugs.

Business Editors/Health/Medical Writers

VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 9, 2003

InNexus Biotechnology, Inc. (the "Company") announced today the scientific publication and disclosure of a monoclonal-antibody-based, delivery system for intracellular targets utilizing SuperAntibody technology ("SAT").

The publication, performed at the laboratory of Immpheron, Inc., Lexington, Kentucky, by Drs. Sybille Muller, Yungfeng Zhao and Heinz Kohler, co-authored by Dr. Thomas Brown, Wright State University School, Dayton, Ohio, has shown that monoclonal antibodies can be used to target intracellular proteins important to the regulation of cellular activities; specifically, the process of genetically regulated cell-suicide ("apoptosis"). A monoclonal antibody to a key enzyme (caspase 3), involved in the apoptotic cascade, was modified with SAT which imparted the ability to penetrate into cells without incurring toxicity. The modified antibody rapidly entered cells, bound to its target, and inhibited its activity. Thus even with prior exposure of the cells to the toxic chemotherapeutic drug actinomycin D, the cells did not die. The SuperAntibody was compared to the best-known small molecule inhibitor, a peptide, and produced comparable inhibition. The peptide inhibitor, though potent, is also toxic and cannot be used in patients or animals.

The publication points to an even broader use of InNexus's cell-penetrating antibodies, that is, their use as an alternative in some small-molecule drug development. Until now, intracellular targets important in the regulation of biological processes have been typically targeted with hydrophobic small molecules. Such small molecules are intended to cross cell membranes in addition to binding and inhibiting, or turning on, cell processes. Non-hydrophobic drugs, even small molecule RNA oligonucleotides, which may have increased specificity compared to traditional small molecule drugs, still require a delivery system to allow them to cross cell membranes. In contrast, monoclonal antibodies offer the highest level of specificity of any drug development approach and are not inherently toxic because of their molecular nature. Until now, however, antibodies could only be used to target cell surface molecules. With InNexus's SAT, which is simple and non-toxic, important intracellular molecules can be targeted with antibodies.

Dr. Charles Morgan, President of InNexus commented, "We are pleased by this timely, proof-of-principle study that allows us to expand the uses of monoclonal antibodies and SuperAntibody Technology. We believe its extrapolation as an alternative to small molecule drug design is readily supportable while its importance to the regulation of cell death initiated by stroke, neurologic disease or even aging is self-apparent".

The peer-reviewed publication referenced herein is published online at www.kluweronline.com and will be in print in December. The citation is: "MTS-conjugated, anti-active caspase 3 antibodies inhibit actinomycin D-induced apoptosis", Y Zhao, T L Brown, H Kohler and S. Muller. Apoptosis 8 (6): 631-637 December 2003.

About InNexus

InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus will develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs.

On behalf of the Board of Directors of InNexus Biotechnology Inc.

Dr. A. Charles Morgan, President

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.